Fixed-Dose Combination Drugs: Why does the Government ban FDCs?

The Centre has banned 16 more Fixed-Dose Combination Drugs to eliminate irrational drug combinations that pose risks to public health. Read here to learn more.

The Union Ministry of Health and Family Welfare (MoHFW) has prohibited the manufacture, sale, and distribution of 16 Fixed-Dose Combination drugs across India with immediate effect under Section 26A of the Drugs and Cosmetics Act, 1940.

The decision aims to eliminate irrational drug combinations that pose risks to public health and strengthen India’s efforts to ensure safe, effective, and evidence-based medicines.

Read: Indian Pharmaceutical Industry

What are Fixed-Dose Combination Drugs?

A Fixed-Dose Combination (FDC) is a pharmaceutical formulation containing two or more Active Pharmaceutical Ingredients (APIs) combined in a fixed proportion within a single dosage form, such as a tablet, capsule, or syrup.

The objective of FDCs is to:

• Improve patient compliance by reducing pill burden.
• Enhance therapeutic effectiveness through complementary drug actions.
• Simplify treatment regimens.
• Reduce healthcare costs in long-term therapy.

Common Examples

• Anti-tuberculosis drugs
• HIV/AIDS medications
• Anti-diabetic combinations
• Hypertension medicines
• Antimalarial therapies

How are FDCs Developed?

FDCs are prepared by combining multiple active pharmaceutical ingredients into a single formulation after scientific evaluation of:

• Pharmacological compatibility
• Therapeutic effectiveness
• Safety profile
• Appropriate dosage ratio

Well-designed FDCs provide synergistic benefits. However, irrational combinations without scientific evidence can cause serious health risks.

Why are Some FDCs Considered Irrational?

An FDC becomes irrational when:

• The combined drugs have no therapeutic justification.
• One ingredient adds no clinical benefit.
• The dosage ratio is inappropriate.
• The combination increases adverse drug reactions.
• It promotes unnecessary antibiotic use.
• It complicates dose adjustment.
• It contributes to antimicrobial resistance (AMR).

Legal Framework

Drugs and Cosmetics Act, 1940

Section 26A empowers the Central Government to prohibit or regulate the manufacture, sale, or distribution of any drug if it is satisfied that:

• It poses a risk to human health.
• It lacks therapeutic value.
• Safer alternatives are available.
• The risk outweighs the benefits.

The current ban has been imposed under this provision.

Key Features of the Ban

1. Ban on 16 Irrational FDCs

The prohibition covers 16 fixed-dose combination medicines across various therapeutic categories, including:

• Skin creams
• Painkillers
• Antispasmodic medicines
• Antibiotic combinations

These combinations were found to have an unfavourable risk-benefit profile.

2. Immediate Nationwide Enforcement

The notification became effective immediately. Manufacturers are required to:

• Stop manufacturing
• Cease distribution
• Withdraw existing stocks
• Halt retail sale

3. Strengthening Drug Safety

The ban forms part of the Government’s larger campaign against:

• Irrational medicines
• Unsafe over-the-counter (OTC) products
• Substandard pharmaceutical formulations
• Misuse of antibiotics

Why is the Ban Important?

Enhances Patient Safety

Removing irrational FDCs reduces:

• Drug toxicity
• Allergic reactions
• Adverse drug interactions
• Medication errors

Thereby protecting patients from avoidable health risks.

Combats Antimicrobial Resistance (AMR)

One of the major concerns is the irrational use of antibiotics.

Unnecessary antibiotic combinations:

• Encourage resistant bacteria.
• Reduce the effectiveness of life-saving antibiotics.
• Increase healthcare costs.
• Make infections harder to treat.

The ban supports India’s National Action Plan on Antimicrobial Resistance (NAP-AMR).

Promotes Rational Drug Use

The measure encourages:

• Evidence-based prescribing
• Scientific drug development
• Rational pharmacotherapy
• Better clinical outcomes

Improves Quality of Healthcare

• Removing unsafe medicines enhances public confidence in India’s pharmaceutical regulatory system and aligns drug approvals with international standards.

Challenges Associated with Irrational FDCs

• Easy availability without adequate medical supervision.
• Aggressive pharmaceutical marketing.
• Self-medication by patients.
• Inconsistent regulatory approvals in the past.
• Difficulty in monitoring adverse drug reactions.
• Increased burden on the healthcare system due to treatment failures.

Government Measures to Ensure Drug Safety

• Strengthening regulation under the Drugs and Cosmetics Act, 1940.
• Periodic review of approved FDCs by expert committees.
• Strengthening pharmacovigilance through the Pharmacovigilance Programme of India (PvPI).
• Promoting rational prescribing practices.
• Monitoring antibiotic use under the National Action Plan on AMR.
• Enhancing quality surveillance by the Central Drugs Standard Control Organisation (CDSCO).

Way Forward

• Conduct regular scientific review of all marketed FDCs.
• Strengthen post-marketing surveillance and adverse drug reporting.
• Promote evidence-based prescribing among healthcare professionals.
• Increase public awareness about the dangers of self-medication.
• Encourage pharmaceutical innovation focused on clinically justified combinations.
• Harmonise regulatory standards with global best practices, including WHO recommendations.

Conclusion

The ban on 16 irrational Fixed-Dose Combination drugs reflects India’s commitment to ensuring safe, effective, and rational use of medicines.

While well-designed FDCs remain valuable tools for improving treatment adherence and clinical outcomes, scientifically unjustified combinations pose significant risks to public health.

By eliminating unsafe formulations and promoting evidence-based pharmacotherapy, the government has taken a crucial step toward enhancing patient safety, preserving antibiotic effectiveness, and improving the quality of healthcare delivery in India.